# Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

> **NCT02582320** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 264 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02582320
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2018-10
- **Final completion:** 2018-10-03
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582320, "Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02582320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*